Alitretinoin for the treatment of severe chronic hand eczema

Eczema (chronic) - alitretinoin: review decision - October 2012 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 45 KB)

Eczema (chronic) - alitretinoin: review proposal - August 2012 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 52 KB)

Appendix B: Proposal paper presented to the institute's Guidance Executive

Eczema (chronic) - alitretinoin: final appraisal determination information

Eczema (chronic) - alitretinoin: final appraisal determination

Eczema (chronic) - alitretinoin: final appraisal determination (PDF 130 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 158 KB)

Consultee and commentator comments on the ACD

Basilea Medical comments on the ACD

Basilea Medical comments on the ACD (PDF 47 KB)

Basilea Medical comments on the evaluation report

Basilea Medical comments on the evaluation report (PDF 22 KB)

British Association of Dermatologists

British Association of Dermatologists (PDF 29 KB)

Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham

Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham (PDF 16 KB)

Department of Health

Department of Health (PDF 11 KB)

NHS Centre for Reviews & Dissemination and Centre for Health Economics - York

NHS Centre for Reviews & Dissemination and Centre for Health Economics - York (PDF 10 KB)

Royal College of Nursing

Royal College of Nursing (PDF 18 KB)

Royal College of Physicians

Royal College of Physicians (PDF 17 KB)

Skin Care Campaign and National Eczema Society

Skin Care Campaign and National Eczema Society (PDF 39 KB)

Comments from website consultation

Eczema (chronic) - alitretinoin: appraisal consultation

Eczema (chronic) - alitretinoin: appraisal consultation document information

Eczema (chronic) - alitretinoin: evaluation report

Eczema (chronic) - alitretinoin: pre-meeting briefing

Eczema (chronic) - alitretinoin: pre-meeting briefing (PDF 104 KB)

Eczema (chronic) - alitretinoin: Evidence Review Group report

Eczema (chronic) - alitretinoin: Evidence Review Group report (PDF 525 KB)

Eczema (chronic) - alitretinoin: non-manufacturer submissions

Eczema (chronic) - alitretinoin: Basilea Medical submission

Eczema (chronic) - alitretinoin: Basilea Medical submission (PDF 1.52 MB)

Eczema (chronic) - alitretinoin: Royal College of Physicians

Eczema (chronic) - alitretinoin: Royal College of Physicians (PDF 7.9 KB)

Eczema (chronic) - alitretinoin: British Contact Dermatitis Society

Eczema (chronic) - alitretinoin: British Contact Dermatitis Society (PDF 42 KB)

Eczema (chronic) - alitretinoin: manufacturer submission

Eczema (chronic) - alitretinoin: NICE clarification letter

Eczema (chronic) - alitretinoin: NICE clarification letter (PDF 1.37 MB)

Eczema (chronic) - alitretinoin: manufacturer response to clarification letter

Eczema (chronic) - alitretinoin: manufacturer response to clarification letter (PDF 1.37 MB)

Eczema (chronic) - alitretinoin: expert written personal statements

Eczema (chronic) - alitretinoin: Ormerod

Eczema (chronic) - alitretinoin: Ormerod (PDF 14 KB)

Eczema (chronic) - alitretinoin: Langford

Eczema (chronic) - alitretinoin: Langford (PDF 45 KB)

Eczema (chronic) - alitretinoin: Johnston

Eczema (chronic) - alitretinoin: final scope

Eczema (chronic) - alitretinoin: comments on the draft scope

Eczema (chronic) - alitretinoin: final matrix: of consultees and commentators

Eczema (chronic) - alitretinoin: draft scope

Eczema (chronic) - alitretinoin: comments on the draft matrix 

Eczema (chronic)- alitretinoin: draft matrix of consultees and commentators